审核状态: Project audit state: |
通过审核 Successful |
注册号: Registration number: |
ChiCTR2000029381 |
最近更新时间: Date of Last Refreshed on: |
2020/1/27 20:41:18 |
注册号状态: |
预注册 |
Registration Status: |
Prospective registration |
填写语言: |
中文和英文 |
Language: |
Chinese And English |
注册题目: |
血必净注射液治疗新型冠状病毒感染的肺炎疗效的前瞻性对照研究 |
Public title: |
A prospective comparative study for Xue-Bi-Jing injection in the treatment of pneumonia cause by novel coronavirus infection |
注册题目简写: |
|
Public title acronym: |
|
研究课题的正式科学名称: |
血必净注射液治疗新型冠状病毒感染的肺炎疗效的前瞻性对照研究 |
Scientific title: |
A prospective comparative study for Xue-Bi-Jing injection in the treatment of pneumonia cause by novel coronavirus infection |
研究课题的正式科学名称简写: |
|
Scientific title acronym: |
|
研究课题代号(代码): Study subject ID: |
|
在其它机构的注册号: Secondary ID: |
ChiMCTR2000002938 |
申请注册联系人: |
刘学松 |
研究负责人: |
钟南山/宋元林/邱海波/黎毅敏/刘晓青 |
Applicant: |
Liu Xuesong |
Study leader: |
Zhong Nanshan / Song Yuanlin/Qiu Haibo/Li Yimin/Liu Xiaoqinqing |
申请注册联系人电话: Applicant telephone: |
+86 13611189816 |
研究负责人电话: Study leader's telephone: |
+86 020 34294311 |
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
申请注册联系人电子邮件: Applicant E-mail: |
wpq312@163.com |
研究负责人电子邮件: Study leader's E-mail: |
ylsong70@163.com |
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
申请注册联系人通讯地址: |
北京市海淀区联慧路101号西晴公寓B座928室 |
研究负责人通讯地址: |
广州市越秀区沿江西路151号 |
Applicant address: |
Room 928, block B, Xiqing apartment, 101 Lianhui Road, Haidian District, Beijing, China |
Study leader's address: |
151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China |
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
申请人所在单位: |
广州医科大学附属第一医院 |
||
Applicant's institution: |
The First Affiliated Hospital of Guangzhou Medical University |
是否获伦理委员会批准: |
是 |
||
Approved by ethic committee: |
Yes |
||
伦理委员会批件文号: Approved No. of ethic committee: |
医研伦审2020第16号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
批准本研究的伦理委员会名称: |
广州医科大学附属第一医院医学伦理委员会 |
||
Name of the ethic committee: |
Medical Ethic committee of the First Affiliated Hospital of Guangzhou Medical University |
||
伦理委员会批准日期: Date of approved by ethic committee: |
2020-01-24 | ||
国家FDA批准文号: Approved No. of SFDA: |
国家FDA批准附件: Approved file of SFDA: |
|
|
国家FDA批准日期: Date of approved by SFDA: |
研究实施负责(组长)单位: |
广州医科大学附属第一医院 |
||||||||||||||||||||||
Primary sponsor: |
The First Affiliated Hospital of Guangzhou Medical University |
||||||||||||||||||||||
研究实施负责(组长)单位地址: |
广州市越秀区沿江西路151号 |
||||||||||||||||||||||
Primary sponsor's address: |
151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China |
||||||||||||||||||||||
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
经费或物资来源: |
研究者自筹 |
||||||||||||||||||||||
Source(s) of funding: |
Researcher self-financing |
||||||||||||||||||||||
研究疾病: |
2019新型冠状病毒感染的肺炎 |
||||||||||||||||||||||
Target disease: |
Pneumonia infected with new coronavirus in 2019 |
||||||||||||||||||||||
研究疾病代码: |
|
||||||||||||||||||||||
Target disease code: |
|
||||||||||||||||||||||
研究类型: |
干预性研究 |
||||||||||||||||||||||
Study type: |
Interventional study |
||||||||||||||||||||||
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
Study phase: |
4 |
||||||||||||||||||||||
研究目的: |
评价血必净对肺炎严重指数(PSI) 的改善作用 ,及 28天预后的影响。 |
||||||||||||||||||||||
Objectives of Study: |
To evaluate the effect of Xuebijing on the improvement of pneumonia severity index (PSI) and the 28-day prognosis. |
||||||||||||||||||||||
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
Study design: |
Non randomized control |
||||||||||||||||||||||
纳入标准: |
1. 经病原学检测确诊的新型冠状病毒感染的肺炎 2. 符合社区获得性肺炎诊断标准(依据 2019 ATS/IDSA诊断标准) 3. 肺炎严重指数( PSI)Ⅲ)Ⅲ-Ⅴ级或 氧合指数(P/F)≤300 mmHg 4. 18≤年龄 75周岁 5. 签署知情同意书 |
||||||||||||||||||||||
Inclusion criteria |
1. New coronavirus-infected pneumonia confirmed by pathogenic detection; 2. Meet the diagnostic criteria for community-acquired pneumonia (based on 2019 ATS/IDSA diagnostic criteria); 3. Pneumonia Severity Index (PSI) III-V or Oxygenation Index (P/F)<=300 mmHg; 4. Aged 18 to 75 years; 5. Obtain informed consent. |
||||||||||||||||||||||
排除标准: |
1. 孕妇、哺乳期妇女 2. 过敏体质,或对血必净注射液及其成分过敏者 3. 影响生存的严重基础疾病,包括:未控制已经多处转移不能切除的恶性肿瘤、血液病、恶液质、活动性 出血、严重营养不良、 HIV等 4. 肺部肿瘤致阻塞性肺炎、严重肺间质纤维化、肺泡蛋白沉积症、过敏性肺泡炎者 5. 近 6个月内持续使用免疫抑制剂,或器官移植者 6. 体外生命支持(ECMO、 ECCO2R、 RRT) 7. 预计48小时内死亡者 |
||||||||||||||||||||||
Exclusion criteria: |
1. Pregnancy or lactating women; 2. People with allergies or allergies to Xuebijing injection and its components; 3. Severe basic diseases that affect survival, including: uncontrolled malignant tumors with multiple metastases that cannot be removed, hematological diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.; 4. Obstructive pneumonia caused by lung tumors, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic reaction alveolitis; 5. Previous immunosuppressive agents within 6 months before study entry or recipients of a solid-organ or bone marrow transplant; 6. Extracorporeal life support (ECMO, ECCO2R, RRT); 7. Expected to die within 48 hours. |
||||||||||||||||||||||
研究实施时间: Study execute time: |
从From2020-01-01至To 2020-12-31 |
干预措施: Interventions: |
|
研究实施地点: Countries of recruitment and research settings: |
|
测量指标: Outcomes: |
|
采集人体标本:
Collecting sample(s)
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Pending |
年龄范围: Participant age: |
|
||||||
性别: |
男女均可 |
Gender: |
Both |
||||||
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
UTN(全球唯一识别码): |
盲法: |
N/A |
Blinding: |
N/A |
试验完成后的统计结果: |
|
Calculated Results ater
|
|
研究负责(组长)单位: |
|
Organizer institution (leader institution): |
|
资料收集汇总单位: |
6M |
Data collection Institution: |
|
资料管理单位: |
广州呼吸健康研究院 |
Data management Institution: |
Guangzhou Institute of Respiratory Health |
资料分析单位: |
广州呼吸健康研究院 |
Data analysis Institution: |
Guangzhou Institute of Respiratory Health |